Adiponectin in coronary heart disease and newly diagnosed impaired glucose tolerance
|
|
- Estella Mathews
- 6 years ago
- Views:
Transcription
1 0179DVR / Diabetes & Vascular Disease ResearchAzizi Ghanbari et al. Original Article Adiponectin in coronary heart disease and newly diagnosed impaired glucose tolerance Diabetes & Vascular Disease Research 10(5) The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / dvr.sagepub.com Aline Azizi Ghanbari 1, Rolf Dörr 3, Stefan Spitzer 3, Juergen Stumpf 3, Andreas Britz 2, Ildiko Amann-Zalan 4, Volker Lodwig 4, Bernhard Ulm 5, Oliver Schnell 5 and Tobias Lohmann 1 Abstract Objective: Adiponectin is produced by adipose tissue and regarded as protective hormone for diabetes and coronary heart disease (CHD). Its role in heart failure is discussed controversially. Methods: In this study, 1015 consecutive patients admitted for acute (n = 149) or elective (n = 866) coronary angiography were enrolled. Patients with known diabetes mellitus (DM) were excluded. All patients were classified by oral glucose tolerance test (ogtt) according to World Health Organization (WHO) criteria and by the results of coronary angiography as no/minor coronary heart disease (CHD), single-vessel disease (1-VD), double-vessel disease (2-VD) or triple-vessel disease (3-VD), by New York Heart Association (NYHA) criteria and by echocardiography for heart failure. Adiponectin and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were measured in all patients. Results: Adiponectin was higher in patients with normal glucose tolerance (NGT) (13.65 ± mg/l) compared to impaired glucose tolerance (IGT) (11.12 ± 7.5, p < 0.001) or diabetes (11.22 ± 7.63, p < 0.001). There was a stepwise decrease in adiponectin from no CHD (18.16 ± mg/l) to minor CHD (16.01 ± 11.42) to 1-VD (12.18 ± 8.8, p < to no/minor CHD) to 2- and 3-VD (10.68 ± 7.5, p < to no/minor CHD, p = to 1-VD). Patients with heart failure NYHA III (17.4 ± 10.27) had higher adiponectin levels compared to NYHA II (12.94 ± 9.41, p < to NYHA III) and NYHA I (10.3 ± 7.75, p < to NYHA III/II). In this line, adiponectin levels were positively correlated to NT-proBNP levels (r = 0.303), and patients with ejection fraction (EF) < 50% had higher adiponectin levels than those with EF > 50% (14.96 ± 4.35 to ± 3.71, p = 0.006). Conclusion: Adiponectin levels are inversely correlated to progressing CHD and glucose intolerance but positively correlated to increasing heart failure. Keywords Adiponectin, coronary heart disease, diabetes mellitus, heart failure Introduction Adiponectin is an adipocyte-secreted protein associated with insulin resistance, increased body weight and cardiovascular dysfunction and may have anti-inflammatory properties. 1 It was originally identified by four independent groups and also called as Acrp30, GBP28, apm1 and AdipoQ. 2 5 Low adiponectin levels predict future risk of developing type 2 diabetes. 6 Moreover, adiponectin levels are decreased in patients with coronary heart disease (CHD), 7 and high adiponectin levels predict a lower risk of future myocardial infarction. 8 However, high adiponectin levels are surprisingly associated with increased risk of recurrent cardiovascular events 9 and mortality in patients with myocardial infarction 10 and heart failure Therefore, it may be difficult to use adiponectin levels in individual patients to predict risk of cardiovascular disease or mortality. 1 Department of Medicine, Municipal Hospital of Dresden-Neustadt, Dresden, Germany 2 Central Laboratory, Municipal Hospital of Dresden-Neustadt, Dresden, Germany 3 Praxisklinik Herz und Gefässe, Dresden, Germany 4 Roche Diagnostics GmbH, Mannheim, Germany 5 Diabetes Research Group at the Helmholtz Center, Munich, Germany Corresponding author: Tobias Lohmann, Department of Medicine, Municipal Hospital of Dresden-Neustadt, Industriestr. 40, Dresden, Germany. tobias.lohmann@khdn.de
2 Azizi Ghanbari et al. 453 We have investigated a large cohort (n > 1000) of unselected patients admitted to coronary catheterization without known diabetes. All patients were clinically well characterized, exactly stated for coronary findings and underwent standardized oral glucose tolerance test (ogtt). We looked whether adiponectin levels correlated to (1) glucose dysregulation in this early stage of disease, (2) extent of coronary disease in catheterization and (3) extent of cardiac dysfunction defined by New York Heart Association (NYHA) state, ejection fraction (EF) and N-terminal probrain natriuretic peptide (NT-proBNP) levels. Research design and methods Study population In this study, 1015 consecutive patients admitted for coronary catheterization to the Praxisklinik Herz und Gefässe, Dresden, Germany, from June 2007 to June 2009 were included. Altogether, 149 patients were admitted for acute coronary syndrome and 866 patients for routine catheterization. Data on patients are published elsewhere. 14 In summary, 319 patients were female, mean age was 68.2 years and mean body mass index (BMI) was 27.4 kg/m 2. Patients with known diabetes mellitus (DM) were excluded as were patients with known endocrine, pancreatic, hepatic or chronic kidney diseases [estimated glomerular filtn rate (egfr) < 50 ml/min]. All patients provided written consent, and the study was performed in accordance with the Declan of Helsinki (approval by the local ethics committee, Sächsische Ärztekammer registn no. EK-BR-36/06-1). After ogtt, patients were classified as follows: with normal glucose tolerance (NGT) (n = 513), with impaired fasting glucose (IFG) (n = 10), with impaired glucose tolerance (IGT) (n = 349) and with DM (n = 143). For analysis, the groups with IFG and IGT were summarized as one group due to the small number of patients with IFG. After catheterization, patients were classified as no CHD (n = 63), minor CHD (n = 183), single-vessel disease (1-VD) (n = 222), double-vessel disease (2-VD) (n = 225) and triplevessel disease (3-VD) (n = 322). For analysis, the groups of 2-VD and 3-VD were summarized as multiple-vd. Heart failure was defined clinically by NYHA classification: NYHA I (n = 324), NYHA II (n = 566) and NYHA III (n = 63). Nearly all (999/1015) the patients also had echocardiography with estimation of EF. Laboratory analyses All patients underwent an ogtt on the day after the coronary angiography. After an overnight fast for at least 10 h, a standard ogtt (75 g of glucose in 250 ml of water) was performed between 8:00 a.m. and 10:00 a.m. according to World Health Organization (WHO) recommendations. 15 Figure 1. Adiponectin and glucose tolerance. Adiponectin levels in patients with normal glucose tolerance (NGT), impaired glucose tolerance [IGT, including patients with impaired fasting glucose (IFG), see Research design and methods section] and patients with diabetes mellitus (DM). The diagnosis of diabetes according to the ogtt results was based on the WHO Consulting Group Criteria: 15 venous fasting plasma glucose (FPG) 126 mg/dl (7 mmol/l) and/or 2-h post-load plasma glucose after an ogtt 200 mg/dl (11.1 mmol/l). 15 IGT was defined as FPG < 126 mg/dl (7.0 mmol/l) and 2-h post-load plasma glucose 140 mg/dl (7.8 mmol/l) and <200 mg/dl (11.1 mmol/l) by WHO criteria. 15 IFG was defined as FPG 100 mg/dl (5.6 mmol/l) and FPG < 126 mg/dl (7 mmol/l) using American Diabetes Association (ADA) criteria. 16 NGT was defined as FPG < 100 mg/dl (5.6 mmol/l) and 2-h post-load plasma glucose < 140 mg/dl (7.8 mmol/l) by WHO criteria. 15 Plasma glucose, HbA 1c, lipid levels, creatinine, electrolytes, blood count, lipids and C-reactive protein were analysed in the Central Laboratory of the Municipal Hospital of Dresden-Neustadt by routine methods. Whole adiponectin was measured by enzyme-linked immunosorbent assay (ELISA) kit purchased from Mediagnost GmbH, and NT-proBNP was measured by Enzyme Light Fluorescence Assay of Roche Diagnostics GmbH. Adiponectin levels are demonstrated as mean ± standard deviation (SD) in text and median + 25/75 and 10/90 percentiles in Figures 1 to 4. Coronary angiography Coronary angiography was performed by the Judkins method or modified Sones technique with direct puncture of either brachial or radial artery in the catheterization laboratory of the Praxisklinik Herz und Gefaesse, Dresden. CHD
3 454 Diabetes & Vascular Disease Research 10(5) Figure 2. Adiponectin and stage of coronary heart disease. Adiponectin levels in patients with no coronary heart disease (no CHD), minor coronary heart disease (minor CHD), singlevessel disease (1-VD) and double- or triple-vessel disease (2- or 3-VD). Figure 4. Adiponectin and ejection fraction in echocardiography. Adiponectin levels in patients with ejection fraction (EF) < 50% and > 50% in echocardiography as indicated. by independent visual assessment of two experienced interventional cardiologists and, at the 50% diameter stenosis threshold, by computer-based quantitative coronary angiography (QCA) as follows: no angiographic evidence of obstructive CHD, minor CHD with lesions of <50% diameter narrowing, 1-VD, 2-VD or 3-VD. 17 Statistical methods Figure 3. Adiponectin and NYHA state of heart failure. Adiponectin levels in patients with NYHA states I, II and III as indicated. NYHA: New York Heart Association. was defined based on the results of the coronary angiography as follows no CHD: normal luminal diameter of any coronary artery, minor CHD: <50% stenosis of any coronary artery, 1-VD: >50% of any coronary artery disease, 2-VD: >50% stenosis of two different main coronary arteries and 3-VD: >50% stenosis of three different main coronary arteries. Coronary angiography findings were classified Because of the sample size, a normal distribution of the means could be assumed; the analysis of variance (ANOVA) with the Tukey Kramer post hoc test and the student s t-test were used to compare adiponectin levels between patient groups. A p value of 0.05 was regarded as significant. In Figures 1 to 4, outliers are shown and are defined by a distance greater than 1.5-fold (outlier) or 3-fold (extreme outlier) of the interquartile range between 25th and 75th quartiles. All outliers were included into the statistical analysis. Furthermore, correlation between adiponectin and NT-proBNP levels was tested by Pearson method. By multivariate logistic regression model, we have controlled whether the correlation of adiponectin levels to glucose tolerance state; the extent of coronary disease and state of heart failure were independent of possible confounders such as age, sex and other known cardiovascular risk factors. SPSS version 14 for Windows was used for statistical analysis. Results Adiponectin and glucose tolerance Adiponectin was higher in patients with NGT (13.65 ± mg/l) compared to IFG/IGT (11.12 ± 7.5 mg/l,
4 Azizi Ghanbari et al. 455 Table 1. Adiponectin dependence from glucose tolerance (IGT/IFG or DM compared to NGT). Overall Male Female odds odds odds IFG and IGT Intercept Adiponectin Age BMI HDL Triglyceride Creatinine DM Intercept Adiponectin Age BMI HDL Triglyceride Creatinine IFG: impaired fasting glucose; IGT: impaired glucose tolerance; CI: confidence interval; BMI: body mass index; HDL: high-density lipoprotein; DM: diabetes mellitus. Significant results are given in boldface. p < to NGT) or DM (11.22 ± 7.63 mg/l, p < to NGT, non-significant to IFG/IGT) (Figure 1). There was no significant difference in adiponectin levels in elective (12.62 ± 9.29 mg/l) compared to acute investigated patients (11.25 ± 8.04 mg/l). Adiponectin and CHD There was a stepwise decrease in adiponectin levels from no CHD (18.16 ± mg/l) to minimal CHD (16.01 ± mg/l, non-significant to no CHD) to 1-VD (12.18 ± 8.8 mg/l, p < to no and minimal CHD) and to 2- and 3-VD (10.68 ± 7.5 mg/l, p < to no and minor CHD, p = to 1-VD) (Figure 2). Adiponectin and heart failure Patients with heart failure NYHA III (17.4 ± mg/l) had higher adiponectin levels compared to patients with NYHA II (12.94 ± 9.41 mg/l, p < to NYHA III) and NYHA I (10.3 ± 7.75 mg/l, p < to NYHA III and II) (Figure 3). Moreover, adiponectin levels were positively correlated to NT-proBNP levels (r = 0.303, p < 0.001). Patients with EF < 50% had higher adiponectin levels (14.96 ± 4.35 mg/l) compared to patients with EF 50% (11.78 ± 3.71 mg/l, p = 0.006) (Figure 4). Correlation of adiponectin with known risk factors of cardiovascular disease We found a positive correlation of adiponectin to whole cholesterol (r = 0.204, p < 0.001), high-density lipoprotein (HDL) cholesterol (r = 0.473, p < 0.001) and low-density lipoprotein (LDL) cholesterol (r = 0.176, p < 0.001) and a negative correlation to triglycerides (r = 0.247, p < 0.001). There was no difference in adiponectin levels between patients with and without hypertension or patients with and without family history of CHD, but smokers had lower levels of adiponectin than non-smokers (both for actual and ever smoking, p < compared to never smoking), and patients with normal body weight (BMI < 25) had higher adiponectin levels (13.95 ± 9.73 mg/l) compared to patients with overweight (BMI = , adiponectin = 12.0 ± 9.25 mg/l, p = 0.004) and adipositas (BMI 30, adiponectin = ± 7.69 mg/l, p = 0.015). As adiponectin levels differ according to gender (men = 9.99 ± 6.71, women = ± 11.23, p < ), the regression analysis was performed overall and split into men and women. Multivariate binary regression analysis shows that for IGT compared to NGT, adiponectin levels, age and BMI showed significant results in all three analysis [for odds (OR), see Table 1]. Neither HDL nor creatinine revealed a significant influence in any group. Triglyceride was significant in the overall regression but not in the gender-specific calculations. Diabetes compared to NGT showed significant results in terms of age and triglyceride for all groups. HDL and creatinine had no significance in any group. Adiponectin was only significant in the female population, and BMI was significant in the overall comparison and in the male group. For extent of coronary disease, 1-VD compared to no CHD, no factor had a significant influence in all three groups. Age was significant in the overall and in the female group, and adiponectin and creatinine were significant only in the overall group. In
5 456 Diabetes & Vascular Disease Research 10(5) Table 2. Adiponectin dependence from extent of CHD (minor CHD, 1-VD and 2- or 3-VD compared to no CHD). Overall Male Female Minor CHD Intercept Adiponectin Age BMI HDL Triglyceride Creatinine VD Intercept Adiponectin Age BMI HDL Triglyceride Creatinine VD or 3-VD Intercept Adiponectin Age BMI HDL Triglyceride Creatinine CI: confidence interval; BMI: body mass index; HDL: high-density lipoprotein; CHD: coronary heart disease; : exponentiation of the B coefficient; 1-VD: singlevessel disease; 2-VD: double-vessel disease; 3-VD: triple-vessel disease. Significant results are given in boldface. comparison between 2-VD/3-VD and no CHD for all patients, adiponectin, age, HDL and creatinine appeared as significant influences. Adiponectin was the only significant factor in men, and age and HDL were the significant factors in female patients (for OR, see Table 2). NYHA II compared to I indicated, in the overall analysis, significances in adiponectin, age and BMI (all OR > 1). Those three variables and creatinine showed significant results in the male patient group (all OR > 1). No factor had a significant influence on the female patient group. On comparing NYHA III and I levels, adiponectin, age and BMI presented significant effect in the overall and in the male group (all OR > 1). Adiponectin, age and creatinine had significant impact in the female group (all OR > 1) (for results, see Table 3). Conclusion In the literature, there are data about decreased adiponectin levels in DM and CHD. 1,7,8 Low adiponectin levels have been associated with insulin resistance as a key finding in type 2 diabetes and CHD. 18,19 Along this line, our study found higher adiponectin levels in patients with suspected CHD and NGT compared to patients with newly diagnosed IGT and type 2 diabetes. In multivariate analysis, this difference holds true for women but not for men. Although these patients without known diabetes may be expected in an early phase of their disease, many of them had already progressed CHD from catheterization findings. Again in line with the known literature, 20 we found a stepwise decrease in adiponectin levels with progressing CHD in catheterization findings. Currently, it is not clear whether adiponectin is a real protective factor in the coronary disease process or more a bystander reflecting other risk factors. In our population, we found a negative correlation to other risk factors such as smoking habits, obesity, glucose intolerance or triglycerides (or positive correlation to the protective HDL cholesterol). Against expectations, we also found a positive correlation to LDL and whole cholesterol. The high correlation to HDL cholesterol is remarkable and in agreement with previous data. 21 But there is direct evidence for protective influence of adiponectin on cardiac function in the literature. 22,23 In multivariate analysis, sex differences were obvious the significant correlation between adiponectin levels and extent of coronary disease was shown for male but not for female patients possibly due to age being a main confounder in female patients. In contrast, HDL cholesterol
6 Azizi Ghanbari et al. 457 Table 3. Adiponectin dependence from NYHA state (II and III compared to I) each with confounders of age, BMI, HDL, triglyceride, creatinine and split into men/women. Overall Male Female NYHA II Intercept Adiponectin Age BMI HDL Triglyceride Creatinine NYHA III Intercept Adiponectin Age BMI HDL Triglyceride Creatinine CI: confidence interval; BMI: body mass index; HDL: high-density lipoprotein; : exponentiation of the B coefficient; NYHA: New York Heart Association. Significant results are given in boldface. was a main confounder in both sexes in agreement with the high correlation described above. 21 Arguing against a pure protective role of adiponectin in CHD, we found a positive correlation of adiponectin to progressing heart failure as judged by NYHA state, NT-proBNP or EF. Similar findings were reported. 13,24 26 It is not clear whether this increase in adiponectin levels may be a counter-regulatory process or a pathophysiological detrimental factor. It has been described that NT-proBNP is able to stimulate adiponectin secretion in adipocytes. 25 Also, in our study, there is a positive correlation of NT-proBNP and adiponectin levels as described elsewhere. 27,28 Moreover, there is evidence of a local adiponectin secretion in cardiomyocytes, but this secretion seems to be much less than from adipocytes and not measurable in blood plasma. 29,30 Some authors blame cachexia in heart failure for increasing adiponectin levels, 28 but this reason is not likely in our patients with early and mild heart failure NYHA II/III or I. The strength of our study is a large population of clinically well-characterized patients attending a routine catheterization laboratory investigation without previous known IGT. Therefore, these patients seemed to be in an early phase of metabolic vascular disease although already progressed vascular findings were seen in catheterization. We confirm a negative correlation of adiponectin levels with both progressing glucose intolerance and cardiovascular disease. The interpretation of adiponectin levels for individual patients may be confusing, however, by increase in the adiponectin levels even in earlier states of heart failure (NYHA II or III). Acknowledgements The authors thank the staff of the study unit of the Praxisklinik Herz und Gefässe and of the Central Laboratory of the Municipal Hospital of Dresden-Neustadt for organizing patient recruitment and lab analyses. A.A.G., R.D., S.S., J.S., I.A.Z., O.S., and T.L. are responsible for conception and design, analysis and interpretation of the data; drafting the article; revising the article and for final approval of the version to be published. B.U. is responsible for statistical analysis of data and revising the article critically for important intellectual content. A.B. is responsible for laboratory analysis and also revising the article critically for important intellectual content. Conflict of interest statement I.A.Z. and V.L. are employees of Roche Diagnostics GmbH, which markets assays of biomarkers for cardiovascular disease such as NT-proBNP. There are no other conflicting interests to declare. Funding The Silent diabetes study was sponsored by an unrestricted grant of Roche Diagnostics GmbH. References 1. Karatergiou K, Mohamed-Ali V, Jahangiri M, et al. Adiponectin for prediction of cardiovascular risk? Br J Diabetes Vasc Dis 2009; 9: Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270:
7 458 Diabetes & Vascular Disease Research 10(5) 3. Hu E, Liang P and Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: Maeda K, Okubo K, Shimomura I, et al. cdna cloning and expression of a novel adipose specific collagen-like factor, apm1 (AdiPose Most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GFP28, a novel gelatin-binding protein. J Biochem 1996; 120: Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: Wilson SR, Sabatine MS, Wiviott SD, et al. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin or ator- Vastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J 2011; 161: Lindberg S, Pedersen SH, Mogelvang R, et al. Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2012; 109: Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: Tsutamato T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007; 28: Wannamethee SG, Whincup PH, Lennon L, et al. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007; 167: Doerr R, Hoffmann U, Otter W, et al. Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography. Diabetologia 2011; 54: World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Geneva: WHO Department of Noncommunicable Disease Surveillance, American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27(Suppl. 1): S15 S Reiber JHC, Serruys PW, Kooimann CJ, et al. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineograms. Circulation 1985; 71: Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentns of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression of type 2 diabetes in rhesus monkeys. Diabetes 2001; 50: Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: Von Eynatten M, Schneider JG, Humpert PM, et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol 2006; 47: Zietz B, Herfarth H, Paul G, et al. Adiponectin represents an independent cardiovascular risk factor predicting HDLcholesterol levels in type 2 diabetes. FEBS Lett 2003; 545: Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10: Shibata R, Izumiya Y, Sato K, et al. Adiponectin protects against the development of systolic dysfunction following myocardial function. J Mol Cell Cardiol 2007; 42: Shinmura K. Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease. Heart Fail Rev 2010; 15: Tsukamato O, Fujita M, Kato M, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol 2009; 53: Singer JR, Palmas W, Teresi J, et al. Adiponectin and allcause mortality in elderly people with type 2 diabetes. Diabetes Care 2012; 35: Haugen E, Furukawa Y, Isic A, et al. Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: a hospital cohort study. Int J Cardiol 2008; 125: McEntegart MB, Awede B, Petrie MC, et al. Increase in serum adiponectin concentn in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007; 28: Ding G, Qin Q, He N, et al. Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma. J Mol Cell Cardiol 2007; 43: Pineiro R, Iglesias MJ, Gallego R, et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 2005; 579:
Associations among Lifestyle Status, Serum Adiponectin Level and Insulin Resistance
ORIGINAL ARTICLE Associations among Lifestyle Status, Serum Adiponectin Level and Insulin Resistance Hirokazu YOKOYAMA, Hiroshi HIROSE, Hideki OHGO* and Ikuo SAITO Abstract Objective The aim of this study
More informationATHEROSCLEROTIC cardiovascular complications are the leading cause of. Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease
Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease To Decrease Plasma Adiponectin Levels Kuei-Chuan CHAN, 1 MD, Hsi-Hsien CHOU, 1 PhD, Der-Jinn WU, 1 PhD, Yi-Liang WU, 1 MD, and Chien-Ning
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationHbA1c is associated with intima media thickness in individuals with normal glucose tolerance
Diabetes Care Publish Ahead of Print, published online October 6, 2009 Glucose metabolism and IMT HbA1c is associated with intima media thickness in individuals with normal glucose tolerance Thomas Bobbert,
More informationATEF ELBAHRY,FACA,FICA,MISCP,FVBWG.
Hyperglycemia and Coronary Events: where is the link? ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG. Cardiovascular (CV) disease is the primary complication of diabetes ~65% of deaths are due to CV disease Coronary
More informationImpact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
More informationChanges and clinical significance of serum vaspin levels in patients with type 2 diabetes
Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes L. Yang*, S.J. Chen*, G.Y. Yuan, D. Wang and J.J. Chen Department of Endocrinology, Affiliated Hospital of Jiangsu
More informationAdiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance.
ORIGINAL ARTICLE Adiponectin, TG/HDL-cholesterol index and hs-crp. Predictors of insulin resistance. Bonneau GA y Pedrozo WR 1 Ministry of Public Health, Province of Misiones, 2 School of Exact, Chemical
More information902 Biomed Environ Sci, 2014; 27(11):
902 Biomed Environ Sci, 2014; 27(11): 902-906 Letter to the Editor Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationCorrelation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.
Correlation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.) Researcher: Dr. Atthakorn Wutthimanop, MD. Research adviser: Dr.PrinVathesathokit,
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationAndrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University
CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients
More informationpulmonary artery vasoreactivity in patients with idiopathic pulmonary arterial hypertension
Supplementary material Jonas K, Magoń W, Waligóra M, et al. High density lipoprotein cholesterol levels and pulmonary artery vasoreactivity in patients with idiopathic pulmonary arterial hypertension Pol
More informationSerum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting glucose: The Rancho Bernardo Study
Diabetes Care Publish Ahead of Print, published online June 9, 2009 Serum uric acid and incident DM2 Serum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationA diponectin is a collagen-like plasma protein produced
528 CARDIOVASCULAR MEDICINE Implications of plasma concentrations of adiponectin in patients with coronary artery disease Y Nakamura, K Shimada, D Fukuda, Y Shimada, S Ehara, M Hirose, T Kataoka, K Kamimori,
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationAssociation between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese
Diabetes Care Publish Ahead of Print, published online June 12, 2008 Raised Blood Pressure and Dysglycemia Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese Bernard My Cheung,
More informationType 2 diabetes mellitus is associated with lower serum adiponectin level in Bangladeshi population Abstract
16 Mediscope 2015;2(2):16-21 www.gmc.edu.bd ISSN: 2307-7689 Mediscope The Journal of GMC ORIGINAL ARTICLE Type 2 diabetes mellitus is associated with lower serum adiponectin level in Bangladeshi population
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationLow fractional diastolic pressure in the ascending aorta increased the risk of coronary heart disease
(2002) 16, 837 841 & 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Low fractional diastolic pressure in the ascending aorta increased the risk
More informationThe American Diabetes Association estimates
DYSLIPIDEMIA, PREDIABETES, AND TYPE 2 DIABETES: CLINICAL IMPLICATIONS OF THE VA-HIT SUBANALYSIS Frank M. Sacks, MD* ABSTRACT The most serious and common complication in adults with diabetes is cardiovascular
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationEpidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl
Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still
More informationLDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC
Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationTable S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).
Table S1. Characteristics associated with frequency of nut (full entire sample; Nn=4,416). Daily nut Nn= 212 Weekly nut Nn= 487 Monthly nut Nn= 1,276 Infrequent or never nut Nn= 2,441 Sex; n (%) men 52
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationDivision of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan
Association between continuously elevated C-reactive protein and restenosis after percutaneous coronary intervention using drug-eluting stent in angina patients Division of Cardiovascular Medicine, Jichi
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationBiomarkers in risk prediction of heart and kidney disease
Biomarkers in risk prediction of heart and kidney disease Winfried März Medizinische Universität Graz, Medizinische Klinik V Medizinische Fakultät Mannheim, Universität Heidelberg, Synlab Akademie, Mannheim
More informationDECLARATION OF CONFLICT OF INTEREST. None
DECLARATION OF CONFLICT OF INTEREST None BURDEN OF CORONARY ARTERY DISEASE IN DIABETES IN INDIA Amal Kumar Banerjee MD, DM,FACC,FESC,FACP,FAPSC,FICC President Association of Physicians of India SAARC Cardiac
More informationDecreased Serum Levels of Adiponectin Are a Risk Factor for the Progression to Type 2 Diabetes in the Japanese Population
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Decreased Serum Levels of Adiponectin Are a Risk Factor for the Progression to Type 2 Diabetes in the Japanese Population
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationSerum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease
Serum Creatinine and Blood Urea Nitrogen Levels in Patients with Coronary Artery Disease MAK Akanda 1, KN Choudhury 2, MZ Ali 1, MK Kabir 3, LN Begum 4, LA Sayami 1 1 National Institute of Cardiovascular
More informationRelationship between Arterial Stiffness and the Risk of Coronary Artery Disease in Subjects with and without Metabolic Syndrome
243 Original Article Hypertens Res Vol.30 (2007) No.3 p.243-247 Relationship between Arterial Stiffness and the Risk of Coronary Artery Disease in Subjects with and without Metabolic Syndrome Yutaka KOJI
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationDiabetes and the Heart
Diabetes and the Heart Association of Specialty Professors April 4, 2013 Jorge Plutzky, MD Co-Director, Preventive Cardiology Director, The Lipid Clinic Cardiovascular Division Brigham and Women s Hospital
More informationSUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More information300 Biomed Environ Sci, 2018; 31(4):
300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of
More informationMetabolic Syndrome in Asians
Metabolic Syndrome in Asians Alka Kanaya, MD Asst. Professor of Medicine, UCSF Asian CV Symposium, November 17, 2007 The Metabolic Syndrome Also known as: Syndrome X Insulin Resistance Syndrome The Deadly
More informationLIPID GUIDELINES: 2015
LIPID GUIDELINES: 2015 D P Mikhailidis BSc MSc MD FCPP FCP FRSPH FFPM FRCP FRCPath Academic Head Dept. of Clinical Biochemistry (Vascular Disease Prevention Clinics) Royal Free campus University College
More informationEUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium
EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV GUY DE BACKER Ghent University,Belgium ESC Congress 2012, aug.25-29th, Munich, Germany ESC Congress 2012, aug.25-29th, Munich,
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationNormal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis
CLINICAL RESEARCH STUDY Normal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis Gregory A. Nichols, PhD, Teresa A. Hillier, MD, MS, Jonathan B. Brown, PhD, MPP Center for Health Research, Kaiser
More informationPathophysiology and Diagnosis of Heart Failure
Pathophysiology and Diagnosis of Heart Failure Francesco Paneni, MD, PhD, FESC Cardiology Unit Karolinska University Hospital Stockholm, Sweden Cardiology University Hospital Zurich Switzerland francesco.paneni@gmail.com
More informationProf. Samir Morcos Rafla Alexandria Univ. Cardiology Dept.
Obesity as a risk factor for Atrial Fibrillation Prof. Samir Morcos Rafla Alexandria Univ. Cardiology Dept. CardioAlex 2010 smrafla@hotmail.com 1 Obesity has reached epidemic proportions in the United
More informationMaster Class in Preventive Cardiology. The New MI Phenotype OR. Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden
Master Class in Preventive Cardiology The New MI Phenotype OR Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden The New MI Phenotype OR Coronary disease and glucose abnormalities Klas
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationBNP as a Predictor of Cardiovascular Disease and All Cause Mortality. Dr. Thierry Le Jemtel
BNP as a Predictor of Cardiovascular Disease and All Cause Mortality Dr. Thierry Le Jemtel Outline Role of BNP and probnp as relevant biomarkers in cardiac conditions Role of BNP and probnp as relevant
More informationOBESITY IS COMMONLY associated with insulin resistance
0021-972X/01/$03.00/0 Vol. 86, No. 5 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close
More informationIntroduction. CLINICAL RESEARCH Prevention and epidemiology
European Heart Journal (2008) 29, 1307 1315 doi:10.1093/eurheartj/ehn135 CLINICAL RESEARCH Prevention and epidemiology Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationSupplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationSERUM VISFATIN LEVELS IN PATIENTS WITH SUBCLINICAL AND NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS
Acta Medica Mediterranea, 2017, 33: 197 SERUM VISFATIN LEVELS IN PATIENTS WITH SUBCLINICAL AND NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS ASLAN ÇELEBI * MUJGAN GURLER **, DENIZ ÖGÜTMEN KOC *, ALI ABBAS OZDEMIR
More informationTo estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome
Original Research Article To estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome Mohamed Yasar Arafath 1, K. Babu Raj 2* 1 First Year Post Graduate, 2
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationPATIENTS AND METHODS:
BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by erosive synovitis that involves peripheral joints and implicates an important influence in the quality
More informationGDF-15 levels but not NTproBNP levels predict diastolic heart failure in morbid obesity
GDF-15 levels but not NTproBNP levels predict diastolic heart failure in morbid obesity M. Fischer, C. Strack, J. Bruxmeier, F. Wagner, E. Rousseva, G. Schmitz, G. Riegger, A. Baessler Clinic for Internal
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationFrequency of Dyslipidemia and IHD in IGT Patients
Frequency of Dyslipidemia and IHD in IGT Patients *Islam MS, 1 Hossain MZ, 2 Talukder SK, 3 Elahi MM, 4 Mondal RN 5 Impaired glucose tolerance (IGT) is often associated with macrovascular complications.
More informationUniversity of Groningen. BNP and NT-proBNP in heart failure Hogenhuis, Jochem
University of Groningen BNP and NT-proBNP in heart failure Hogenhuis, Jochem IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationEmmanouil S. Brilakis 1{, Joseph P. McConnell 2, Ryan J. Lennon 3, Ahmad A. Elesber 1, Jeffrey G. Meyer 2, and Peter B. Berger 4 * Introduction
European Heart Journal (2005) 26, 137 144 doi:10.1093/eurheartj/ehi010 Clinical research Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic
More informationAdiponectin is independently associated with glycosylated haemoglobin
European Journal of Endocrinology (2004) 150 201 205 ISSN 0804-4643 CLINICAL STUDY Adiponectin is independently associated with glycosylated haemoglobin José Manuel Fernández-Real, Patricia Botas-Cervero
More informationThe changes of serum BDNF, blood lipid and PCI in the elderly patients with coronary heart disease complicated with diabetes mellitus
184 Journal of Hainan Medical University 2016; 22(16): 184-188 Journal of Hainan Medical University http://www.hnykdxxb.com/ The changes of serum BDNF, blood lipid and PCI in the elderly patients with
More informationStatin pretreatment and presentation patterns in patients with acute coronary syndromes
Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationSupplementary Online Content
Supplementary Online Content McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol.
More informationEnergy Balance Equation
Energy Balance Equation Intake Expenditure Hunger Satiety Nutrient Absorption Metabolic Rate Thermogenesis Activity Eat to Live! Live to Eat! EAT TO LIVE Intake = Expenditure Weight Stable LIVE TO EAT
More informationRoadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total
Diabetes and the Metabolic Syndrome in the Asian Population Alka Kanaya, MD Associate Professor of Medicine, UCSF Feb 26, 2010 Roadmap 1. Diabetes in Asian Americans Prevalence in the U.S. Risk factors
More informationStudy of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults
Study of the correlation between growth hormone deficiency and serum leptin, adiponectin, and visfatin levels in adults Z.-P. Li 1, M. Zhang 2, J. Gao 3, G.-Y. Zhou 3, S.-Q. Li 1 and Z.-M. An 3 1 Golden
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationSupplementary Note Details of the patient populations studied Strengths and weakness of the study
Supplementary Note Details of the patient populations studied TVD and NCA patients. Patients were recruited to the TVD (triple vessel disease) group who had significant coronary artery disease (defined
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationImpact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients
2012 International Conference on Life Science and Engineering IPCBEE vol.45 (2012) (2012) IACSIT Press, Singapore DOI: 10.7763/IPCBEE. 2012. V45. 14 Impact of Physical Activity on Metabolic Change in Type
More informationPatient referral for elective coronary angiography: challenging the current strategy
Patient referral for elective coronary angiography: challenging the current strategy M. Santos, A. Ferreira, A. P. Sousa, J. Brito, R. Calé, L. Raposo, P. Gonçalves, R. Teles, M. Almeida, M. Mendes Cardiology
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationTroponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg
Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology
More informationJournal of the American College of Cardiology Vol. 48, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.06.053
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationSMARTool clinical and biohumoral results. Chiara Caselli IFC-CNR
SMARTool clinical and biohumoral results Chiara Caselli IFC-CNR SMARTool Flow chart EVINCI and ARTreat Populations SMARTool: WP1 and WP2 WP1 Objective: To collect retrospective EVINCI clinical and imaging
More information